Verrica Pharmaceuticals Inc. Increase (Decrease) in Contract with Customer, Liability
Verrica Pharmaceuticals Inc. (VRCA) reported Increase (Decrease) in Contract with Customer, Liability of $553.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $304.00K, a 36.80% decline year-over-year.
- Verrica Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $249.00K.
- Verrica Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$782.00K.
- Verrica Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $1.08M.
- Verrica Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was $782.00K.
- Verrica Pharmaceuticals Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $304.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $553.00K 10-Q · filed 2026-08-06 | -$229.00K derived: sum of 3 quarters · filed 2026-08-06 | $854.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $249.00K 10-Q · filed 2026-05-12 | -$533.00K derived: sum of 2 quarters · filed 2026-05-12 | $550.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$782.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $301.00K derived: sum of 2 quarters · filed 2026-03-11 | $782.00K derived: sum of 3 quarters · filed 2026-08-06 | $782.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.56M derived: sum of 2 quarters · filed 2026-08-06 | $1.56M 10-Q · filed 2025-11-14 | $1.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $481.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $481.00K 10-Q · filed 2026-08-06 | $481.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 10-K · filed 2026-03-11 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |